A novel human scFv fragment against TNF-α from de novo design method

Molecular Immunology

Volumn 44, Issue 15, 2007, Pages 3789-3796

  Chang, Hong ^a   Qin, Weisong ^b   Li, Yan ^a,c   Zhang, Jiyan ^a   Lin, Zhou ^a   Lv, Ming ^a   Sun, Yingxun ^a   Feng, Jiannan ^a,c   Shen, Beifen ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NANJING UNIVERSITY   (China)

^c HENAN UNIVERSITY   (China)

Author keywords

Antagonistic peptide; Computer guided molecular modeling method; Human antibody variable region; Scaffold; Single chain antibody; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Z12; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNTHETIC PEPTIDE; TSA1 ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL STRAIN HEK293; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CULTURE MEDIUM; ENERGY; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; COMPUTER-AIDED DESIGN; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PEPTIDE FRAGMENTS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SERUM; THERMODYNAMICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249295603     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.03.020     Document Type: Article

References (34)

1. Beutler B., and Cerami A. The biology of cachetin/TNF. A primary mediator of the host response. Annu. Rev. Immunol. 7 (1989) 625-655
2. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 26 (1999) 16-21
3. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., and Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3127-3131
4. Casset F., Roux F., Mouchet P., Bes C., Chardes T., Granier C., Mani J.-C., Pugnière M., Laune D., Pau B., Kaczorek M., Lahana R., and Rees A. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun. 307 (2003) 198-205
5. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., and Lenardo M.J. A domain in TNF receptors that mediates ligand independent receptor assembly and signaling. Science 288 (2000) 2351-2354
6. Chirinos-Rojas C.L., Steward M.W., and Partidos C.D. A phage-displayed mimotope inhibits tumor necrosis factor-induced cytotoxicity more effectively than the free mimotope. Immunology 96 (1999) 109-113
7. Doring E., Stigler R., Gruz G., von Baehr R., and Schneider-Mergener J. Identification and characterization of a TNF alpha antagonist derived from a monoclonal antibody. J. Mol. Immunol. 31 (1994) 1059-1067
8. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu. Rev. Immunol. 19 (2001) 163-196
9. Feng J., Li Y., Zhang W., and Shen B. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. Immunol. Lett. 98 (2005) 311-316
10. Genst E.D., Areskoug D., Decanniere K., Muyldermans S., and Andersson K. Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design. J. Biol. Chem. 277 (2002) 29897-29907
11. Holliger P., and Hudson P. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 9 (2005) 1126-1136
12. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., and Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N. Engl. J. Med. 345 (2001) 1098-1104
13. Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., Hoess A., Wölle J., Plückthun A., and Virnekäs B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296 (2000) 57-86
14. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., and Gottlieb A.B. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349 (2003) 2014-2022
15. Maini R., St. Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354 (1999) 1932-1939
16. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., and Blosch C.M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337 (1997) 141-147
17. Murakami A., Nishizawa T., Egawa K., Kawada T., Nishikawa Y., Uenaka K., and Ohigash H. New class of linoleic acid metabolites biosynthesized by corn and rice lipoxygenases: suppression of proinflammatory mediator expression via attenuation of MAPK- and Akt-, but not PPARγ-, dependent pathways in stimulated macrophages. Biochem. Pharmacol. 70 (2005) 1330-1342
18. Murakami Y., Shoji M., Hanazawa S., Tanaka S., and Fujisaw S. Preventive effect of bis-eugenol, a eugenol ortho dimer, on lipopolysaccharide-stimulated nuclear factor kappa B activation and inflammatory cytokine expression in macrophages. Biochem. Pharmacol. 66 (2003) 1061-1066
19. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. 2 (2003) 736-746
20. Qin W., Feng J., Zhang W., Li Y., and Shen B. A novel TNF-α antagonizing peptide-Fc fusion protein designed based on CDRs of TNF-α neutralizing monoclonal antibody. Biochem. Biophys. Res. Commun. 322 (2004) 1024-1028
21. Qin W., Feng J., Li Y., Lin Z., and Shen B. Fusion protein of CDR mimetic peptide with Fc inhibit TNF-α induced cytotoxicity. Mol. Immunol. 43 (2006) 660-666
22. Qin W., Feng J., Li Y., Lin Z., and Shen B. De novo design TNF-α antagonistic peptide based on the complex structure of TNF-α with its neutralizing monoclonal antibody Z12. J. Biotechnol. 125 (2006) 57-63
23. Qin W., Feng J., Li Y., Lin Z., and Shen B. A novel domain antibody rationally designed against TNF-α using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides. Mol. Immunol. 44 (2007) 2355-2361
24. Skerra A. Engineered protein scaffolds for molecular recognition. J. Mol. Recognit. 13 (2000) 167-187
25. Smyth M.J., and Johnstone R.W. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc. Res. Technol. 50 (2000) 196-208
26. Steed P.M., Tansey M.G., Zalevsky J., Zhukovsky E.A., Desjarlais J.R., Szymkowski D.E., et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301 (2003) 1895-1898
27. Takasaki W., Kajino Y., Kajino K., Murali R., and Greene M.I. Structure based design and characterization of exocyclic peptidomimetics that inhibit TNF-α binding to its receptor. Nat. Biotechnol. 15 (1997) 1266-1270
28. Taylor S.I. Rational design of peptide agonists of cell-surface receptors. Trends Pharmacol. Sci. 21 (2000) 9-10
29. William V.W., Thomas K.E., Joan V., Mark I.G., and David B.W. Design of bioactive peptides based on antibody hypervariable region structures. J. Biol. Chem. 266 (1991) 5182-5190
30. Williams W.V., Moss D.A., Kieber-Emmons T., Cohen J.A., Myers J.N., Weiner D.B., and Greene M.I. Development of biologically active peptides based on antibody structure. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5537-5541
31. Zaghouani H., Steinman R., Nonacs R., Shah H., Gerhard W., and Bona C. Presentation of a viral T cell epitope expressed in the CDR3 region of a self-immunoglobulin molecule. Science 259 (1993) 224-227
32. Zanetti M. Antigenized antibodies. Nature 355 (1992) 476-477
33. Zanetti M., Rossi F., Lanza P., Filaci G., Lee R.H., and Billetta R. Theoretical and practical aspects of antigenized antibodies. Immunol. Rev. 130 (1992) 125-145
34. Zhang W., Feng J., and Shen B. Identification of binding epitope of a monoclonal antibody (Z12) against human TNF-α using computer modeling and deletion mutant technique. Sci. China Ser. C 47 (2004) 167-174